丹七软胶囊联合曲美他嗪治疗冠心病心绞痛的临床研究
|
摘要
目的研究丹七软胶囊联合盐酸曲美他嗪片治疗冠心病心绞痛的临床疗效。方法选取2015年8月—2018年8月海安市人民医院诊治的冠心病心绞痛患者124例作为研究对象,采用随机对照表法将所有患者分为对照组和治疗组,每组各62例。对照组三餐时口服盐酸曲美他嗪片,1片/次,3次/d;治疗组在对照组治疗的基础上口服丹七软胶囊,4粒/次,3次/d。两组患者持续治疗30 d。观察两组患者的临床疗效和心电图疗效,同时比较两组治疗前后的心绞痛发作情况、血液流变学指标和炎性因子水平。结果治疗后,对照组和治疗组的总有效率分别为80.65%、95.16%,两组比较差异具有统计学意义(P<0.05)。治疗后,对照组和治疗组心电图有效率分别为77.42%、95.16%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者心绞痛发作次数和持续时间均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组心绞痛发作次数和持续时间显著低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血浆比黏度(PSV)、血细胞比容(HCT)、纤维蛋白原(FIB)和全血黏度(WBV)水平均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组血液流变学指标水平均明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)水平显著降低,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组炎性因子水平显著低于对照组,两组比较差异具有统计学意义(P<0.05)。结论丹七软胶囊联合盐酸曲美他嗪片治疗冠心病心绞痛具有较好的临床疗效,能够改善患者心绞痛发作次数和发作持续时间,降低血液流变学指标水平,安全性较高,具有一定的临床推广应用价值。
Objective To study the clinical efficacy of Danqi Soft Capsules combined with Trimetazidine Dihydrochloride Tablets in treatment of coronary heart disease with angina pectoris. Methods Patients(124 cases) with coronary heart disease with angina pectoris in Haian People's Hospital from August 2015 to August 2018 were randomly divided into control and treatment groups, and each group had 62 cases. Patients in the control group were po administered with Trimetazidine Dihydrochloride Tablets at meals, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Danqi Soft Capsules on the basis of control group, 4 grains/time, three times daily. Patients in two groups were treated for 30 d. After treatment, the clinical efficacy and electrocardiogram efficacy in two groups were evaluated, and the attack of angina pectoris, hemorheology indexes, and inflammatory factor level before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment group were 80.65% and 95.16%, and there were differences between two groups(P < 0.05). After treatment, the electrocardiogram efficacies in the control and treatment group were 77.42% and 95.16%, and there were differences between two groups(P < 0.05).After treatment, the frequency and duration of angina pectoris in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the frequency and duration of angina pectoris in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of PSV, HCT, FIB, and WBV in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, hemorheology indexes level in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of TNF-α and CRP in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, inflammatory factor levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Danqi Soft Capsules combined with Trimetazidine Dihydrochloride Tablets has good clinical efficacy in treatment of coronary heart disease with angina pectoris, can improve the frequency and duration of angina pectoris attacks, reduce the levels of hemorheological indicators, with high safety, which has a certain clinical application value.
Objective To study the clinical efficacy of Danqi Soft Capsules combined with Trimetazidine Dihydrochloride Tablets in treatment of coronary heart disease with angina pectoris. Methods Patients(124 cases) with coronary heart disease with angina pectoris in Haian People's Hospital from August 2015 to August 2018 were randomly divided into control and treatment groups, and each group had 62 cases. Patients in the control group were po administered with Trimetazidine Dihydrochloride Tablets at meals, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Danqi Soft Capsules on the basis of control group, 4 grains/time, three times daily. Patients in two groups were treated for 30 d. After treatment, the clinical efficacy and electrocardiogram efficacy in two groups were evaluated, and the attack of angina pectoris, hemorheology indexes, and inflammatory factor level before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment group were 80.65% and 95.16%, and there were differences between two groups(P < 0.05). After treatment, the electrocardiogram efficacies in the control and treatment group were 77.42% and 95.16%, and there were differences between two groups(P < 0.05).After treatment, the frequency and duration of angina pectoris in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the frequency and duration of angina pectoris in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of PSV, HCT, FIB, and WBV in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, hemorheology indexes level in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of TNF-α and CRP in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, inflammatory factor levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Danqi Soft Capsules combined with Trimetazidine Dihydrochloride Tablets has good clinical efficacy in treatment of coronary heart disease with angina pectoris, can improve the frequency and duration of angina pectoris attacks, reduce the levels of hemorheological indicators, with high safety, which has a certain clinical application value.
引文
[1]曾玉杰.冠心病治疗新进展[J].中国全科医学,2007,10(6):437-439.
[2]陈慧敏,许逸飞.曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常的临床研究[J].中国临床药理学杂志,2016,32(11):966-968.
[3]郭旭.丹七软胶囊对冠心病患者的心肌保护及血液流变学改善作用[J].心血管康复医学杂志,2016,25(1):108-110.
[4]国际心脏病学会和协会及世界卫生组织临床命名标准化联合专题组.缺血性心脏病的命名及诊断标准[J].中华心血管病杂志,1981,9(1):75-76.
[5]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:72-73.
[6]戴倩,王俊.不稳定型心绞痛治疗进展[J].疑难病杂志,2007,6(8):505-508.
[7]董吉云,杨志勇,苗年海,等.曲美他嗪治疗老年冠心病稳定性心绞痛临床观察[J].安徽医学,2011,32(4):463-465.
[8]王艳霞.丹七软胶囊结合西药治疗老年冠心病心绞痛疗效观察[J].湖北中医药大学学报,2016,18(2):66-69.
[9]杨倩倩,崔建国,王树娟,等.红细胞比容与老年冠心病患者冠状动脉病变的相关性研究[J].中华老年心脑血管病杂志,2017,19(4):370-373.
[10]伍松姣,梁景云,张以昆,等.不同类型冠心病心绞痛患者血清IL-18和hs-CRP的检测及临床意义[J].检验医学,2009,24(1):36,39.
[11]刘丽军,房保军,信栓力,等.冠心病心绞痛患者血浆肿瘤坏死因子α和基质金属蛋白酶-9变化及其临床意义[J].中西医结合心脑血管病杂志,2013,11(1):22-23.
[2]陈慧敏,许逸飞.曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常的临床研究[J].中国临床药理学杂志,2016,32(11):966-968.
[3]郭旭.丹七软胶囊对冠心病患者的心肌保护及血液流变学改善作用[J].心血管康复医学杂志,2016,25(1):108-110.
[4]国际心脏病学会和协会及世界卫生组织临床命名标准化联合专题组.缺血性心脏病的命名及诊断标准[J].中华心血管病杂志,1981,9(1):75-76.
[5]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:72-73.
[6]戴倩,王俊.不稳定型心绞痛治疗进展[J].疑难病杂志,2007,6(8):505-508.
[7]董吉云,杨志勇,苗年海,等.曲美他嗪治疗老年冠心病稳定性心绞痛临床观察[J].安徽医学,2011,32(4):463-465.
[8]王艳霞.丹七软胶囊结合西药治疗老年冠心病心绞痛疗效观察[J].湖北中医药大学学报,2016,18(2):66-69.
[9]杨倩倩,崔建国,王树娟,等.红细胞比容与老年冠心病患者冠状动脉病变的相关性研究[J].中华老年心脑血管病杂志,2017,19(4):370-373.
[10]伍松姣,梁景云,张以昆,等.不同类型冠心病心绞痛患者血清IL-18和hs-CRP的检测及临床意义[J].检验医学,2009,24(1):36,39.
[11]刘丽军,房保军,信栓力,等.冠心病心绞痛患者血浆肿瘤坏死因子α和基质金属蛋白酶-9变化及其临床意义[J].中西医结合心脑血管病杂志,2013,11(1):22-23.